Pediatric Nephrology最新文献

{"title":"Ambulatory blood pressure variability in prediction of target organ injury: the SHIP AHOY study.","authors":"Coral D Hanevold, Jang Dong Seo, Stephen R Daniels, Bonita E Falkner, Michael A Ferguson, Joseph T Flynn, Julie R Ingelfinger, Philip R Khoury, Marc B Lande, Kevin E Meyers, Mark Mitsnefes, Joshua Samuels, Elaine M Urbina","doi":"10.1007/s00467-025-06803-4","DOIUrl":"10.1007/s00467-025-06803-4","url":null,"abstract":"<p><strong>Background: </strong>Ambulatory hypertension is associated with elevated left ventricular mass index (LVMI), cardiac dysfunction, and increased arterial stiffness in adolescents. Whether the addition of measures of BP variability improves the prediction of subclinical cardiovascular target organ damage (TOD) over mean BP measures is not known.</p><p><strong>Methods: </strong>We assessed clinic and ambulatory BP (ABP), anthropometrics, and TOD in 397 adolescents. ABP means standard deviation (SD), BP, and heart rate (HR) dipping were calculated; coefficients of variability (CV) were calculated (SD/mean) to assess ABP variabilities. Measures of TOD included LVMI, left ventricular hypertrophy (LVH), LV systolic shortening, LV diastolic function (e'/a'), and pulse wave velocity. General linear models were used to determine if increased ABP variability measures were significant determinants of TOD in models containing mean ABP percentiles, age, sex, race/ethnicity, BMI z-score, and HR.</p><p><strong>Results: </strong>Mean participant age was 15.6 ± 1.7 years (63% white, 59% male) with mean casual BP 122.6/71.6 mmHg ±12.4/10.5, and mean awake systolic ABP 124.2/72.0 ± 11.3/7.7 mmHg. In linear models, increased awake CV-DBP and HR dipping were significant determinants of LVMI. CV-HR was an independent determinant of diastolic (e'/a') but not systolic dysfunction. Using logistic regression, the combination of awake and asleep diastolic ABP variability and awake systolic ABP percentile improved the prediction of LVH.</p><p><strong>Conclusions: </strong>Consideration of ABP variability in addition to ABP percentile may aid in identifying adolescents at risk for LVH.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"157-165"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Membranous-like glomerulopathy with masked IgG-k deposits in a pediatric patient with juvenile idiopathic arthritis.","authors":"Priyanka Chati, Jill Krissberg, Kammi Henriksen, Brian Nolan, Meredith Harris","doi":"10.1007/s00467-025-06954-4","DOIUrl":"10.1007/s00467-025-06954-4","url":null,"abstract":"<p><p>Membranous-like glomerulopathy with masked IgG-kappa deposits (MGMID) is a rare entity described primarily among young females with previously diagnosed autoimmune diseases. We present a 12-year-old female with systemic juvenile idiopathic arthritis (sJIA) with persistent non-nephrotic range proteinuria despite normal kidney function. She underwent two kidney biopsies with the second ultimately confirming her diagnosis. The initial biopsy was suggestive of mild C3 glomerulonephritis (C3GN). She was started on an angiotensin-converting enzyme inhibitor (ACE-I) without improvement. Proteinuria progressed to the nephrotic range, prompting initiation of high-dose steroids followed by a steroid taper. Mycophenolate was added during steroid weaning due to ongoing proteinuria. Despite full-dose mycophenolate and ACE-I therapy, a repeat biopsy was performed due to lack of response and revealed MGMID. She remains on full-dose mycophenolate and lisinopril with significant improvement in her proteinuria.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"81-84"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to critical appraisal of \"Thiamin deficiency in children with chronic kidney disease on peritoneal dialysis and its association with dialysis duration and transport peritoneal membrane status\".","authors":"Phakwan Laohathai, Narumon Densupsoontorn","doi":"10.1007/s00467-025-06992-y","DOIUrl":"10.1007/s00467-025-06992-y","url":null,"abstract":"","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"255"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the data-scarce landscape of pediatric hyperkalemia: a perspective on sodium zirconium cyclosilicate.","authors":"Lucas Maciel de Almeida Corrêa, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa, Luiggi Kevin Virgino Brandão, Camilla Cristina Silva Fernandes, Letícia Mantovani Milan, Paula Ramos Carneiro","doi":"10.1007/s00467-026-07333-3","DOIUrl":"10.1007/s00467-026-07333-3","url":null,"abstract":"<p><p>For decades, pediatric hyperkalemia has been managed largely with non-selective cation-exchange resins, despite limitations in tolerability, palatability, and gastrointestinal safety. This perspective reviews the role of sodium zirconium cyclosilicate (SZC) in children and places the pediatric evidence in the context of broader hyperkalemia management. Current pediatric SZC data remain sparse and are derived from a small retrospective cohort of children with chronic kidney disease (CKD) stages 4-5/5D and an in vitro infant formula pretreatment study. Within those constraints, SZC was associated with potassium reduction in acute and chronic settings, favorable tolerability, stable serum sodium and blood pressure, and high acceptability, which is relevant in pediatrics, where palatability and adherence often determine effectiveness. The available literature also suggests practical pediatric applications, including age-based oral dosing and formula-pretreatment strategies, although no validated weight-based regimen has been established. Beyond potassium lowering, SZC may support a more individualized approach to potassium management in selected children, potentially reducing the need for broad dietary restriction and helping preserve renin-angiotensin-aldosterone system inhibitor therapy when hyperkalemia becomes a limiting factor. However, these broader clinical implications remain preliminary, largely observational, and partly extrapolated from adult data. Accordingly, SZC should not yet be viewed as an established pediatric practice standard, but rather as a promising adjunct for carefully selected patients in whom older resins are poorly tolerated or ongoing hyperkalemia compromises diet quality or cardiorenal therapy. Until prospective pediatric trials better define dosing, safety, and patient-centered outcomes, any off-label use should remain individualized and closely monitored.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4305-4310"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing children with chronic kidney disease and severe proteinuria in the United States: a retrospective analysis using electronic health records.","authors":"Bradley A Warady, Simone Heeg, Alfredo E Farjat, Rachel Knapp, Siir Su Saydam, Alexander Vowinkel, Alain Gay, James Potts, Andrea Scalise, Gordana Atanackovic, Sascha van Boemmel-Wegmann","doi":"10.1007/s00467-026-07435-y","DOIUrl":"10.1007/s00467-026-07435-y","url":null,"abstract":"<p><strong>Background: </strong>In recent years, real-world data have been increasingly used to enrich data from interventional studies on treatment effectiveness. To explore the viability of hybrid study designs in pediatric chronic kidney disease (CKD), we assessed the feasibility of identifying a real-world cohort of children with CKD and severely increased proteinuria who satisfied adapted eligibility criteria from the FIONA trial.</p><p><strong>Methods: </strong>We used data from the Optum® de-identified Electronic Health Record dataset (Optum® EHR) to identify and characterize children with CKD and severely increased proteinuria in records from January 2013 to December 2022. Patients were identified based on two sets of estimated glomerular filtration rate (eGFR)/serum creatinine and urine protein-to-creatinine ratio (UPCR) measures within a 90- to 365-day period (final date = index). Patients were required to satisfy adapted eligibility criteria from the FIONA trial and have a baseline prescription for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs). Patients were stratified by eGFR and UPCR. Patient characteristics, comorbidities, and medications were descriptively reported.</p><p><strong>Results: </strong>We identified a total of 381 children with CKD and severely increased proteinuria (median age: 14 years; 52.6% male), among whom 80.8% had eGFR ≥ 60 mL/min/1.73 m² and 69.0% had UPCR > 1 g/g. The patient distribution by CKD stage was: G1, 50.9%; G2, 29.9%; G3-4, 19.2%. Among 397 patients who were excluded given no baseline ACEi/ARB use, > 20% initiated ACEi/ARBs within 6 months following index.</p><p><strong>Conclusions: </strong>Our study demonstrated the feasibility of identifying a real-world pediatric cohort with CKD and severely increased proteinuria using adapted criteria from the FIONA trial. Findings from this study highlight factors that should be considered in the design of future hybrid studies evaluating treatment effectiveness using data from both trials and the real world.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4487-4500"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between urinary soluble CD163 and endocapillary proliferation and fibrinoid necrosis in IgA vasculitis with nephritis.","authors":"Xiaoqing Yang, Zhen Zhang, Yueli Yang, Liangliang Bi, Xianqing Ren, Ying Ding, Xia Zhang, Li Zhou, Yanjie Huang","doi":"10.1007/s00467-026-07444-x","DOIUrl":"10.1007/s00467-026-07444-x","url":null,"abstract":"<p><strong>Background: </strong>CD163 is a surface marker expressed by M2c macrophages. This study aims to evaluate the level of urinary soluble CD163 (u-sCD163) in children with IgA vasculitis with nephritis (IgAVN) and its potential diagnostic value.</p><p><strong>Methods: </strong>U-sCD163 was analyzed in 73 children with IgAVN who underwent a kidney biopsy, 37 children with IgA nephropathy and 50 normal controls. CD163 expression was analyzed by immunohistochemistry. Correlation analyses and inter-group comparison were performed to assess the association between u-sCD163 levels and clinicopathological features of IgAVN. The comparison of u-sCD163 levels before and after treatment was conducted.</p><p><strong>Results: </strong>The level of u-sCD163 was significantly higher in children with IgAVN than healthy controls. Compared with grade II IgAVN subjects, u-sCD163 level was significantly elevated in grade III-IV subjects. There was no difference in u-sCD163 level between IgAVN and IgA nephropathy groups. There was no difference in serum CD163 level among different groups. In the IgAVN group, abundant CD163-positive cells were observed in glomeruli showing endocapillary proliferation, especially in areas of thrombosis and fibrinoid necrosis. In contrast, CD163-positive cells were scarce within cellular crescents, but increased in fibrocellular crescents. Levels of u-sCD163 showed a significant positive correlation with proportions of endocapillary proliferation, and moderately correlated with proteinuria, CD163 score of glomerular area, and weakly correlated with proportions of cellular crescents, D-dimer and fibrin degradation products (FDP). The level of u-sCD163 decreased significantly after treatment.</p><p><strong>Conclusions: </strong>U-sCD163 emerges as a promising marker associated with endocapillary proliferation and coagulation in pediatric patients with IgAVN.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4461-4469"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of urinary trehalase levels in the early diagnosis of acute kidney injury in dehydrated children.","authors":"Onur Dağdeviren, Alper Kaçar, Fatma Ece Dağdeviren, Demet Alaygut, Hasan Dursun","doi":"10.1007/s00467-026-07424-1","DOIUrl":"10.1007/s00467-026-07424-1","url":null,"abstract":"<p><strong>Background: </strong>Trehalase is a brush-border glycoprotein enzyme found in the small intestine and in renal proximal tubules, where it breaks down trehalose into glucose. We examined whether a non-invasive urine measurement of trehalase could help with earlier recognition of acute kidney injury (AKI) in children presenting with acute dehydration.</p><p><strong>Methods: </strong>We included 80 children who were evaluated in the Pediatric Emergency Department for acute dehydration and 40 healthy controls from the general pediatric outpatient clinic. Baseline laboratory data were extracted from the hospital information system. At time of presentation, blood and urine specimens were collected from all participants. Urinary trehalase and urinary creatinine levels were analyzed, and the urinary trehalase/creatinine ratio was subsequently computed.</p><p><strong>Results: </strong>Participants were analyzed in three groups: dehydrated with AKI (n = 40), dehydrated without AKI (n = 40), and healthy controls (n = 40). Baseline urea and creatinine and presentation creatinine values were similar between all groups (p > 0.05). At presentation, however, urea, urinary trehalase, and the trehalase-to-creatinine ratio were higher in dehydrated children than in controls (p = 0.001, p = 0.001 and p = 0.026 respectively). Within the dehydrated cohort, children with AKI had higher urinary trehalase, a higher trehalase-to-creatinine ratio, and higher presentation urea than those without AKI (p = 0.023, p = 0.049, and p = 0.001, respectively). Urinary trehalase showed high diagnostic accuracy (AUC 0.925); at a cut-off > 9.55 mg/dL specificity reached 100%.</p><p><strong>Conclusions: </strong>Urinary trehalase, particularly when adjusted for urinary creatinine may capture early tubular injury in dehydrated children before serum creatinine rises. Larger studies are needed to establish clinically useful cut-offs and to confirm diagnostic performance.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4471-4480"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure control in pediatric hemodialysis: data from the SCOPE collaborative.","authors":"Celina Brunson, Mark Mitsnefes, Natalie Grills, Troy Richardson, Audrey Anaya, Diane Kraynak, Alicia M Neu, Bradley A Warady","doi":"10.1007/s00467-026-07448-7","DOIUrl":"10.1007/s00467-026-07448-7","url":null,"abstract":"<p><strong>Background: </strong>The Standardizing Care to Improve Outcomes in Pediatric End Stage Kidney Disease (SCOPE) collaborative is a quality improvement initiative focused on improving care of children on dialysis. Accurate blood pressure (BP) measurement is a focus of SCOPE as cardiovascular disease is a leading cause of morbidity and mortality.</p><p><strong>Methods: </strong>An analysis of children from 25 pediatric hemodialysis (HD) centers enrolled in SCOPE was conducted to describe prevalence of high BP and hypertension and assess risk factors for hypertension. Data on patient characteristics, including age, renal diagnosis, race, sex, and use of antihypertensive medications was collected. Based on 2017 AAP hypertension guidelines, patients were classified as having uncontrolled, controlled or untreated BP as well as persistent hypertension. Generalized linear modeling was used to evaluate associations between patient characteristics and persistent hypertension.</p><p><strong>Results: </strong>A total of 3532 BP evaluation forms from 407 HD patients were collected, providing 6962 BP measurements. 54.3% of BP measurements were abnormal with 25.4% classified as stage I hypertension and 16.3% as stage II hypertension. Across 3532 forms, 47.7% showed uncontrolled BP, 13.8% showed untreated hypertension and 37.1% had persistent hypertension. There were no significant associations of age, renal diagnosis, race or sex with persistent hypertension.</p><p><strong>Conclusions: </strong>Prevalence of uncontrolled and untreated hypertension is high among patients on HD in the SCOPE collaborative, despite frequent use of antihypertensive therapy. This mirrors results from other registry studies but is more robust due to use of repeated measurements, standardized measurement procedures and use of post-HD measurements for classification of hypertension.</p>","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4481-4486"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of short-term outcomes in patients with anti-factor H associated atypical HUS managed with plasma exchanges versus eculizumab.","authors":"Aditi Sinha, Tanvi Bindal, Federica Zotta, Anne-Laure Sellier-Leclerc, Julien Hogan, Pankaj Hari, Marina Vivarelli, Arvind Bagga","doi":"10.1007/s00467-026-07309-3","DOIUrl":"10.1007/s00467-026-07309-3","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Antibodies to factor H (anti-FH) are a leading cause of atypical hemolytic uremic syndrome (aHUS) in school-going children. While terminal complement blockade with eculizumab (ECZ) is standard of care for all forms of aHUS, anti-FH associated aHUS is uniquely amenable to combination therapy with plasma exchange (PEX) and immunosuppression. There are no controlled comparisons on the relative short- or medium-term efficacy of the two strategies of management.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The primary objectives were to compare the time from initiation of therapy to hematological remission and renal recovery between patients managed with PEX versus ECZ, with or without immunosuppression, for anti-FH associated aHUS in native kidneys. We also compared the proportions of patients attaining hematological remission or renal recovery by 7, 14 and 28 days of therapy, and proportion of patients with chronic kidney disease G1-5, dialysis-dependence, or death.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data sources: &lt;/strong&gt;PubMed and Embase were searched from January 2004 to April 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study eligibility criteria: &lt;/strong&gt;Studies, in English language, were eligible if they reported the time to hematological remission and renal recovery in individual patients with anti-FH antibody-associated aHUS in native kidneys and treated with either PEX or ECZ with or without additional immunosuppression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants and interventions: &lt;/strong&gt;Within studies, individual patients were included if they had received either, and not both, PEX or ECZ, and information regarding time to hematological remission and renal recovery was available.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study appraisal and synthesis methods: &lt;/strong&gt;The risk of bias for retrospective cohort studies and case reports or series was assessed using the Newcastle-Ottawa Quality Assessment Scale and Joanna Briggs Institute (JBI) tool for systematic reviews, respectively. Individual patient data were combined by therapy group to report time-to-event outcomes as hazard ratios (95% confidence intervals, CI), compared using the log rank test. Other continuous measures were compared between groups using the rank sum test.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Fourteen of 57 studies shortlisted from among 403 search results met eligibility criteria, within which 99 patients, including 81 managed with PEX and 18 with ECZ, with/without immunosuppression, were eligible. Patients receiving PEX presented later with more severe anemia and lower eGFR, and more often required dialysis. Median time to hematologic remission was significantly shorter with PEX (9 vs. 20 days; P = 0.0007) while time to renal recovery was similar (16 vs. 20 days; P = 0.36). The proportion with CKD G3-5 and mortality was insignificantly higher with PEX than ECZ (respective P 0.077 and 0.36).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;Our findings are limited by small numbers of participants and studies, lack of comparative studies, heterog","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4369-4378"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two decades of trust: reflections on a partnership transforming paediatric kidney care in Guatemala.","authors":"Randall Lou-Meda, Marina Wainstein","doi":"10.1007/s00467-026-07476-3","DOIUrl":"10.1007/s00467-026-07476-3","url":null,"abstract":"","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4243-4247"},"PeriodicalIF":2.5,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148562703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}